TARSUS PHARMACEUTICALS, INC. Stock-Based Compensation
TARSUS PHARMACEUTICALS, INC. (TARS) reported Stock-Based Compensation of $25.26 million for the 6-month period ending 2026-06-30, per its 10-Q filed 2026-08-06.
Financial Statements › Cash Flow › Operating Activities
us-gaap:ShareBasedCompensation · last filed 2026-08-06
- TARSUS PHARMACEUTICALS, INC. share-based payment arrangement, noncash expense for the quarter ending 2026-06-30 was $13.29M, a 61.41% increase year-over-year.
- TARSUS PHARMACEUTICALS, INC. share-based payment arrangement, noncash expense for the quarter ending 2026-03-31 was $11.97M, a 72.68% increase year-over-year.
- TARSUS PHARMACEUTICALS, INC. share-based payment arrangement, noncash expense for the quarter ending 2025-12-31 was $14.31M, a 93.35% increase year-over-year.
- TARSUS PHARMACEUTICALS, INC. share-based payment arrangement, noncash expense for the quarter ending 2025-09-30 was $12.24M, a 65.11% increase year-over-year.
- TARSUS PHARMACEUTICALS, INC. share-based payment arrangement, noncash expense for fiscal 2025 was $41.72M, a 49.97% increase from fiscal 2024.
- TARSUS PHARMACEUTICALS, INC. share-based payment arrangement, noncash expense for fiscal 2024 was $27.82M, a 40.28% increase from fiscal 2023.
- TARSUS PHARMACEUTICALS, INC. share-based payment arrangement, noncash expense for fiscal 2023 was $19.83M, a 47.33% increase from fiscal 2022.
- TARSUS PHARMACEUTICALS, INC. share-based payment arrangement, noncash expense for fiscal 2022 was $13.46M, a 59.20% increase from fiscal 2021.
| Period end | Share-based Payment Arrangement, Noncash Expense 3 month | Share-based Payment Arrangement, Noncash Expense 6 month | Share-based Payment Arrangement, Noncash Expense 9 month | Share-based Payment Arrangement, Noncash Expense 12 month |
|---|---|---|---|---|
| 2026-06-30 | $13.29M derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-06 | $25.26M 10-Q · filed 2026-08-06 | $39.57M derived: sum of 3 quarters · filed 2026-08-06 | $51.81M derived: sum of 4 quarters · filed 2026-08-06 |
| 2026-03-31 | $11.97M 10-Q · filed 2026-05-06 | $26.28M derived: sum of 2 quarters · filed 2026-05-06 | $38.52M derived: sum of 3 quarters · filed 2026-05-06 | $46.76M derived: sum of 4 quarters · filed 2026-08-06 |
| 2025-12-31 | $14.31M derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-23 | $26.56M derived: sum of 2 quarters · filed 2026-02-23 | $34.79M derived: sum of 3 quarters · filed 2026-08-06 | $41.72M 10-K · filed 2026-02-23 |
| 2025-09-30 | $12.24M derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-04 | $20.48M derived: sum of 2 quarters · filed 2026-08-06 | $27.41M 10-Q · filed 2025-11-04 | $34.81M derived: sum of 4 quarters · filed 2026-08-06 |
| 2025-06-30 | $8.23M derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-06 | $15.16M 10-Q · filed 2026-08-06 | $22.57M derived: sum of 3 quarters · filed 2026-08-06 | $29.98M derived: sum of 4 quarters · filed 2026-08-06 |
| 2025-03-31 | $6.93M 10-Q · filed 2026-05-06 | $14.33M derived: sum of 2 quarters · filed 2026-05-06 | $21.75M derived: sum of 3 quarters · filed 2026-05-06 | $29.23M derived: sum of 4 quarters · filed 2026-05-06 |
| 2024-12-31 | $7.40M derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-23 | $14.82M derived: sum of 2 quarters · filed 2026-02-23 | $22.30M derived: sum of 3 quarters · filed 2026-02-23 | $27.82M 10-K · filed 2026-02-23 |
| 2024-09-30 | $7.42M derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-04 | $14.90M derived: sum of 2 quarters · filed 2025-11-04 | $20.41M 10-Q · filed 2025-11-04 | $25.90M derived: sum of 4 quarters · filed 2026-02-23 |
| 2024-06-30 | $7.48M derived: 10-Q 6 month − 10-Q 3 month · filed 2025-08-06 | $13.00M 10-Q · filed 2025-08-06 | $18.48M derived: sum of 3 quarters · filed 2026-02-23 | $23.73M derived: sum of 4 quarters · filed 2026-02-23 |
| 2024-03-31 | $5.52M 10-Q · filed 2025-05-01 | $11.00M derived: sum of 2 quarters · filed 2026-02-23 | $16.25M derived: sum of 3 quarters · filed 2026-02-23 | $21.44M derived: sum of 4 quarters · filed 2026-02-23 |
| 2023-12-31 | $5.48M derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-23 | $10.73M derived: sum of 2 quarters · filed 2026-02-23 | $15.92M derived: sum of 3 quarters · filed 2026-02-23 | $19.83M 10-K · filed 2026-02-23 |
| 2023-09-30 | $5.25M derived: 10-Q 9 month − 10-Q 6 month · filed 2024-11-13 | $10.44M derived: sum of 2 quarters · filed 2024-11-13 | $14.35M 10-Q · filed 2024-11-13 | $18.02M derived: sum of 4 quarters · filed 2025-02-25 |
| 2023-06-30 | $5.19M derived: 10-Q 6 month − 10-Q 3 month · filed 2024-08-08 | $9.10M 10-Q · filed 2024-08-08 | $12.77M derived: sum of 3 quarters · filed 2025-02-25 | $16.35M derived: sum of 4 quarters · filed 2025-02-25 |
| 2023-03-31 | $3.91M 10-Q · filed 2024-05-08 | $7.58M derived: sum of 2 quarters · filed 2025-02-25 | $11.16M derived: sum of 3 quarters · filed 2025-02-25 | $14.69M derived: sum of 4 quarters · filed 2025-02-25 |
| 2022-12-31 | $3.67M derived: 10-K 12 month − 10-Q 9 month · filed 2025-02-25 | $7.25M derived: sum of 2 quarters · filed 2025-02-25 | $10.79M derived: sum of 3 quarters · filed 2025-02-25 | $13.46M 10-K · filed 2025-02-25 |
| 2022-09-30 | $3.58M derived: 10-Q 9 month − 10-Q 6 month · filed 2023-11-09 | $7.12M derived: sum of 2 quarters · filed 2023-11-09 | $9.79M 10-Q · filed 2023-11-09 | $11.97M derived: sum of 4 quarters · filed 2023-11-09 |
| 2022-06-30 | $3.53M derived: 10-Q 6 month − 10-Q 3 month · filed 2023-08-10 | $6.21M 10-Q · filed 2023-08-10 | $8.38M derived: sum of 3 quarters · filed 2023-08-10 | $10.50M derived: sum of 4 quarters · filed 2023-08-10 |
| 2022-03-31 | $2.67M 10-Q · filed 2023-05-09 | $4.85M derived: sum of 2 quarters · filed 2023-05-09 | $6.97M derived: sum of 3 quarters · filed 2023-05-09 | $9.77M derived: sum of 4 quarters · filed 2023-05-09 |
| 2021-12-31 | $2.18M derived: 10-K 12 month − 10-Q 9 month · filed 2023-03-17 | $4.30M derived: sum of 2 quarters · filed 2023-03-17 | $7.09M derived: sum of 3 quarters · filed 2023-03-17 | $8.46M 10-K · filed 2023-03-17 |
| 2021-09-30 | $2.12M derived: 10-Q 9 month − 10-Q 6 month · filed 2022-11-09 | $4.91M derived: sum of 2 quarters · filed 2022-11-09 | $6.28M 10-Q · filed 2022-11-09 | $6.71M derived: sum of 4 quarters · filed 2022-11-09 |
| 2021-06-30 | $2.79M derived: 10-Q 6 month − 10-Q 3 month · filed 2022-08-11 | $4.16M 10-Q · filed 2022-08-11 | $4.59M derived: sum of 3 quarters · filed 2022-08-11 | $4.82M derived: sum of 4 quarters · filed 2022-08-11 |
| 2021-03-31 | $1.36M 10-Q · filed 2022-05-11 | $1.80M derived: sum of 2 quarters · filed 2022-05-11 | $2.02M derived: sum of 3 quarters · filed 2022-05-11 | $2.20M derived: sum of 4 quarters · filed 2022-05-11 |
| 2020-12-31 | $438.00K derived: 10-K 12 month − 10-Q 9 month · filed 2022-03-14 | $662.00K derived: sum of 2 quarters · filed 2022-03-14 | $835.00K derived: sum of 3 quarters · filed 2022-03-14 | $839.00K 10-K · filed 2022-03-14 |
| 2020-09-30 | $224.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2021-11-10 | $397.00K derived: sum of 2 quarters · filed 2021-11-10 | $401.00K 10-Q · filed 2021-11-10 | $406.00K derived: sum of 4 quarters · filed 2021-11-10 |
| 2020-06-30 | $173.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2021-08-05 | $177.00K 10-Q · filed 2021-08-05 | $182.00K derived: sum of 3 quarters · filed 2021-08-05 | |
| 2020-03-31 | $4.00K 10-Q · filed 2021-05-11 | $9.00K derived: sum of 2 quarters · filed 2021-05-11 | ||
| 2019-12-31 | $5.00K derived: 10-K 12 month − 10-Q 9 month · filed 2021-03-31 | $18.00K 10-K · filed 2021-03-31 | ||
| 2019-09-30 | $13.00K 10-Q · filed 2020-11-25 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Denali Therapeutics Inc. (DNLI) | United States | $3.274B | -8.04 |
| Relay Therapeutics, Inc. (RLAY) | United States | $3.884B | -14.30 |
| Beam Therapeutics Inc. (BEAM) | United States | $2.549B | -41.51 |
| Greenland Mines Ltd (GRML) | United States | $2.362B | |
| BIOCRYST PHARMACEUTICALS INC (BCRX) | United States | $2.175B | -6.63 |
| ADMA BIOLOGICS, INC. (ADMA) | United States | $2.131B | 11.16 |
| Kodiak Sciences Inc. (KOD) | United States | $2.090B | -10.12 |
| RECURSION PHARMACEUTICALS, INC. (RXRX) | United States | $2.080B | -3.78 |
| Vericel Corp (VCEL) | United States | $2.011B | 93.97 |
| Adaptive Biotechnologies Corp (ADPT) | United States | $4.719B | -53.43 |